Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study

World Journal of Gastroenterology

Volumn 17, Issue 14, 2011, Pages 1879-1888

  Lim, Robert ^a   Sun, Yan ^b   Im, Seock Ah ^c   Hsieh, Ruey Kuen ^d   Yau, Tsz Kok ^e   Bonaventura, Anthony ^f   Cheirsilpa, Arkom ^g   Esser, Regina ^h   Mueser, Matthias ⁱ   Advani, Suresh ^j  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b CANCER HOSPITAL   (China)

^c Seoul National University Hospital   (South Korea)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^f CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^g NATIONAL CANCER INSTITUTE   (Thailand)

^h MERCK KGAA   (Germany)

ⁱ Medical Affairs Oncology Asia Pacifc   (Singapore)

^j JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

more..

Author keywords

Asia; Cetuximab; Epidermal growth factor receptor; Irinotecan; Metastatic colorectal cancer

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN;

ABDOMINAL PAIN; ACNE LIKE RASH; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; AUSTRALIA; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY; INFECTION; INFUSION RELATED REACTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SOUTHEAST ASIA; STOMATITIS; SURVIVAL TIME; VOMITING;

EID: 79955929800     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i14.1879     Document Type: Article

References (28)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN. Cancer incidence, mortality and prevalence worldwide, vol. Version 1.0, 2004: IARC Press, 2002
2. Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221
3. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683
4. Center MM, Jemal A, Ward E. International trends in color-ectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-1694
5. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6: 871-876
6. Adenis A, Aranda Aguilar E, Robin YM, Miquel R, Penault-Llorca F. C. C, Queralt B, Eggleton SP, van den Berg N, Wilke H. Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial. J Clin Oncol 2005; 23 suppl: A3630
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345
8. Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH. Cetuximab and irinotecan/5-fuoroura-cil/folinic acid is a safe combination for the frst-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-456
9. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001; 92: 1331-1346
10. Mayer A, Takimoto M, Fritz E, Schellander G, Kofer K, Lud-wig H. The prognostic signifcance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454-2460
11. Baselga J. The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer 2001; 37 Suppl 4: S16-S22
12. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abu-bakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd. EPIC: phase III trial of cetuximab plus irinotecan after fluoropy-rimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319
13. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Rob-itaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and beneft from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765
14. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH, Siena S. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008; 26: 5335-5343
15. Buzaid AC, Mathias Cde C, Perazzo F, Simon SD, Fein L, Hidalgo J, Murad AM, Esser R, Senger S, Lerzo G. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. Clin Colorectal Cancer 2010; 9: 282-289
16. Brookmeyer R, Crowley J. A confdence interval for the median survival time. Biometrics 1982; 38: 29-41
17. Greenwood M. The natural duration of cancer. Reports on Public Health and Medical Subjects London: Her Majesty's Stationary Offce 1926; 33: 1-26
18. Levine MN, Julian JA. Registries that show effcacy: good, but not good enough. J Clin Oncol 2008; 26: 5316-5319
19. Wilke H, Buzaid A, Mathias C, Lim R, Esser R, Loos A, Van Cutsem E, Cunningham D. Cetuximab in combination with irinotecan in patients after irinotecan failure: An integrated analysis of four studies from different geographic regions. J Clin Oncol 2008 26: suppl: A4062
20. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21: 807-814
21. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fuo-rouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418
22. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Randomised trial of irinotecan versus fuorouracil by continuous infusion after fuorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412
23. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eck-hardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-1135
24. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fuorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-260
25. Siena S, Glynne-Jones R, Adenis A, Thaler J, Preusser P, Aguilar EA, Aapro MS, Loos AH, Esser R, Wilke H. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 2010; 116: 1827-1837
26. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208
27. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the frst-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671
28. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nip-pgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417